KYTH News 36.01 Kythera Biopharmaceuticals Inc (KYTH)

New Post Public Reply Private Reply Replies (0) Message Board

Apr 18, 2014 at 2:28 AM

Kythera Biopharmaceuticals Inc (KYTH) 36.01 $KYTH

Kythera Biopharmaceuticals, Inc. (KYTH) in Focus: Stock Surges 9.9 % - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:44AM CDT
Kythera Biopharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.

Nasdaq stocks posting largest percentage increases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

What Falling Estimates & Price Mean for Kythera (KYTH) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 7:57AM CDT
It may be a good decision to sell Kythera as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a Zacks Rank #4 confirms weakness.

Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma
PR Newswire - Tue Mar 25, 10:00AM CDT
On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:

Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

KYTHERA Biopharmaceuticals Announces 2013 Operating Results
GlobeNewswire - Mon Mar 17, 3:26PM CDT
KYTHERA Biopharmaceuticals, Inc.(Nasdaq:KYTH) today reported financial results for its quarter and year ended December 31, 2013, and provided an update on recent accomplishments.

Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.

Kythera Regains ATX-101 from Bayer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 3:39PM CDT
Kythera regained all rights to ATX-101 outside the U.S. and Canada from the HealthCare segment of Bayer.

Why KYTHERA Biopharmaceuticals Inc. Shares Shot Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 11, 3:12PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of KYTHERA Biopharmaceuticals , a...

KYTHERA Acquires Rights to ATX-101 Outside of the U.S. and Canada From Bayer Consumer Care
GlobeNewswire - Mon Mar 10, 3:05PM CDT
KYTHERA Now Holds Global Rights to ATX-101

KYTHERA Biopharmaceuticals to Release 2013 Operating Results
GlobeNewswire - Mon Mar 10, 9:02AM CDT
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it will release its fourth quarter and full year 2013 operating results and will host an investor call and webcast at 4:30 p.m. ET on Monday, March 17, 2014.

KYTHERA Biopharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Fri Feb 28, 3:33PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the Cowen and Company 34th Annual Health Care Conference in Boston, MA.

MarketMeSuite pilots Constant Contact's Small Business Innovation Program and announces new Constant Contact integration
Business Wire - Wed Feb 19, 8:00AM CST
MarketMeSuite (MarketMeSuite.com), the leading social media management and marketing platform for small businesses and professionals, has integrated with Constant Contact, launched on Constant Contact's MarketPlace, and has been named the first technology partner to join Constant Contact's Small Business Innovation program.

Use Options For A Chance To Buy KYTH At A 17% Discount
at The Street - Wed Feb 12, 10:50AM CST
Looking back to 127 days ago, Kythera Biopharmaceuticals priced a 2,622,950 share secondary stock offering at $45.75 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over...

Stock Price Movements, Conference Presentation Schedules, and Expanded Sharing of Clinical Data - Research Report on Gilead, Express Scripts, Sanofi, Agilent, and Kythera Biopharma
PR Newswire - Wed Jan 08, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Express Scripts Holding Company (NASDAQ: ESRX), Sanofi SA (ADR) (NYSE: SNY), Agilent Technologies Inc. (NYSE: A) and Kythera Biopharmaceuticals Inc. (NASDAQ: KYTH). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

KYTHERA Biopharmaceuticals to Present at 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 06, 3:10PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Kythera Biopharmaceuticals Inc. is now in Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 06, 7:47AM CST
Kythera Biopharmaceuticals Inc. is now in Oversold Territory

Stock Price Movements, FDA Approvals, and Completed Acquisitions - Research Report on AbbVie, Baxter, IDEXX, Kythera Biopharmaceuticals, and Medical Properties Trust
PR Newswire - Tue Dec 24, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.

KYTHERA Biopharmaceuticals Announces Addition to the NASDAQ Biotechnology Index
GlobeNewswire - Thu Dec 19, 4:50PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 23, 2013.

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 16, 7:05AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 23, 2013.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Florida's Natural, Johnsonville Settle Bet Over Juice

No Such Thing as a Safe Bet When Milwaukee's Brewers edge out Tampa, it's not just about the wins and losses—it's about pride and a truckload of Florida's Natural orange juice cruising into Wisconsin. Who knew baseball could drive trades not just between players, but entire industries? In this friendly wager, the stakes were both flavorful and steep, paying homage to...

Veralto Sees Strong Q3 2026 Growth, Eyes 2027 Gains

Veralto's Stellar Third Quarter Performance Jumping right into the thick of it, Veralto's third quarter 2026 numbers aren't just a flash in the pan. We're talking a solid sales boost of 7.5%, reaching the magic number of $1,509 million. If you're holding NYSE:VLTO, these figures are a good look. It's not every day you see an operating profit margin hovered at an...

Samyang Bolsters Sugar Reduction at SupplySide Global

You ever take a stroll around a trade show floor packed with folks jiving over the latest in food and wellness? That's what's going down at SupplySide Global 2026 in Las Vegas, and Samyang Corporation is strutting in with a heap of sugar reduction solutions and dietary fiber goods that would make any nutritionist grin from ear to ear. Debuting Tapioca-Based Resistant...

Navigating Commercial Leases: Insights from Brandon McClain

Beyond the Monthly Rent: Real Lease Considerations When it comes to picking out a commercial space, folks, we ain't just talking square footage and what's scribbled under monthly rent. There's a whole roster of stuff businesses need to vet before getting ink on that dotted line. This ain't just about signing a lease—it's sizing up whether a property plays ball with your...

Banco Santander's Troubles: Legal Heat on SAN

Brazilian Turbulence Shakes Banco Santander Imagine getting hit twice in a single week, once by a surprise election result and again by numbers that don't add up. That's the gut-wrenching scenario Banco Santander's (NYSE: SAN) investors are facing. After Brazil's unexpected election outcome, investor jitters translated into a 3.7% drop on October 26, 2026. Not two days...

David Cornue Brings Story Insights to SXSW 2027

Crafting Stories with Precision: Cornue's Return In the world where Austin becomes a melting pot of ideas every spring, the return of David Cornue to SXSW casts a familiar, yet electrifying spark. This best-selling author and television whiz is slated to share his story magic at two workshops: one in the Lifestyle track and the other in the Film & TV track. Folks on-site...

Xyte's Record Quarter: Surging Demand & New CEO

Setting New Records in the AV Industry There's buzz in the air over in Hoboken, New Jersey. Xyte, the AI cloud maestro you're starting to hear about more and more, has just smashed its own records this past September. It's not just a flash in the pan, either—this isn't the first time they've knocked it out of the park. Thanks to burgeoning enterprise demand and a...

5GAA Brings Cutting-Edge Tech to India’s Roads

India's Mobility Challenge: A Crossroads for Innovation When it comes to road networks, India isn't playing with a small deck—the nation’s highways and byways stretch across vast and complicated landscapes. It's like a massive puzzle we're trying to solve. The bigwigs from the 5G Automotive Association (5GAA) just wrapped up their gig in New Delhi, showing off tech...

Radiation Oncologist Dr. Pennock Honored: A Closer Look

An Honor from The Inner Circle Sometimes, in a field stuffed with brilliant minds, a beacon stands out. That's Dr. Michael M. Pennock for you—a man who doesn’t just treat cancer patients but transforms their journeys with precision and empathy. Recognized as a Pinnacle Lifetime Member by The Inner Circle, Pennock’s dedication in the field of radiation oncology is...

U&I Ventures Raises $32.237M for AI Infrastructure

U&I Ventures Stirs the Pot with Its Debut Fund Here's what I see brewing in the tech sector: when 1,800 top-notch tech leaders come together, you know something's up. U&I Ventures has locked in a $32.237 million fund to tackle AI-native infrastructure in security and engineering. Now, that's a firm that ain't messing around, pulling in the big guns for a big venture. The...